1h Free Analyst Time
CD40 Ligand - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. The CD40-CD40 ligand interaction is crucial to the development of T dependent immune responses. The ligand is expressed on a range of cell types including B cells, granulocytes, macrophages and platelets. T cells expressing CD40L provide signals to B cells that induce proliferation, immunoglobulin class switching, antibody secretion, and rescue from apoptosis at different times during the life of a B cell and also have a role in the development of germinal centres and the survival of memory B cells.
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) pipeline Target constitutes close to 19 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 5 and 7 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System and Genetic Disorders which include indications Autoimmune Disorders, Graft Versus Host Disease (GVHD), Amyotrophic Lateral Sclerosis, Breast Cancer, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Auto Inflammatory Disease, Bladder Cancer, Colon Cancer, Hepatocellular Carcinoma, Inflammation, Kidney Transplant Rejection, Lung Adenocarcinoma, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Pancreatic Islet Transplant Rejection, Sicca Syndrome (Sjogren), Solid Tumor and Transplant Rejection.
The latest report CD40 Ligand - Pipeline Review, H2 2019, outlays comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
- The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects
- The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Overview
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Companies Involved in Therapeutics Development
Anelixis Therapeutics LLC
Bristol-Myers Squibb Co
eTheRNA Immunotherapies NV
Memgen LLC
NapaJen Pharma Inc
Sanofi
Shattuck Labs Inc
TILT Biotherapeutics Ltd
Tonix Pharmaceuticals Holding Corp
UCB SA
Viela Bio Inc
XL-protein GmbH
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drug Profiles
AT-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dapirolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ECI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CD40LG for Genetic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CD40 Ligand for Malignant Melanoma and Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISF-35 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
letolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NJA-730 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-441344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-115154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-172154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TILT-234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-1500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIB-4920 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Dormant Products
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Discontinued Products
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Product Development Milestones
Featured News & Press Releases
Dec 11, 2019: Viela Bio announces initiation of phase 2b trial of VIB4920 in Sjogren’s Syndrome
Nov 08, 2019: UCB Presents new data on investigational molecule Dapirolizumab Pegol at the 2019 American College of Rheumatology and the Association of Rheumatology Professionals (ACR/ARP) Annual Meeting
Aug 21, 2019: Tonix Pharmaceuticals and Massachusetts General Hospital enter into research collaboration to develop Tonixs third generation anti-CD154 monoclonal antibody, TNX-1500, for the treatment and prevention of organ transplant rejection
Jun 01, 2019: Safety and immune stimulation data from an intranodal delivery of TriMix mRNA, in the adjuvant melanoma study E011-MEL
Mar 04, 2019: eTheRNA immunotherapies completes patient enrolment for Phase Ib-study in adjuvant melanoma
Nov 28, 2018: Augie's Quest reports first subject successfully enrolled in AT-1501 phase 1 study, a first-of-its-kind, promising treatment for ALS
Nov 15, 2018: NapaJen Pharma announces first patient dosed in phase 1 first-in-human clinical trial of novel RNA interference (RNAi) therapeutic
Oct 23, 2018: UCB and Biogen announce topline results from a phase 2b study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
Oct 19, 2018: Viela Bio Announces Late-Breaking Abstract Acceptance for VIB4920 at the 2018 ACR/ARHP Annual Meeting
Oct 08, 2018: eTheRNA Opens State-of-the-art Manufacturing Facility in Belgium to Support the Development of its TriMix-based mRNA Cancer Immunotherapies
May 24, 2018: eTheRNA Enrols First Patient in High Dose Cohort of Phase 1b study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma
Mar 19, 2018: eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma
Jun 30, 2017: etherna Advances in-vivo MRNA Cancer Immunotherapy Into First Oncology Clinical Studies
Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016)
Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Anelixis Therapeutics LLC, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by eTheRNA Immunotherapies NV, H2 2019
Pipeline by Memgen LLC, H2 2019
Pipeline by NapaJen Pharma Inc, H2 2019
Pipeline by Sanofi, H2 2019
Pipeline by Shattuck Labs Inc, H2 2019
Pipeline by TILT Biotherapeutics Ltd, H2 2019
Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2019
Pipeline by UCB SA, H2 2019
Pipeline by Viela Bio Inc, H2 2019
Pipeline by XL-protein GmbH, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Anelixis Therapeutics LLC
- Bristol-Myers Squibb Co
- eTheRNA Immunotherapies NV
- Memgen LLC
- NapaJen Pharma Inc
- Sanofi
- Shattuck Labs Inc
- TILT Biotherapeutics Ltd
- Tonix Pharmaceuticals Holding Corp
- UCB SA
- Viela Bio Inc
- XL-protein GmbH
